The central question that prompted this study was to what extent a fully virulent HER2-retargeted oHSV, armed with IL-12, exemplified here by R-115, was able to elicit a local immune response, lymphocytes migration to the tumor and activation, and ultimately local and distant immunotherapeutic efficacy. This evidence concerns the gene ERBB2 and neoplasm.